MAFRivastigmine Transdermal Patch 4.6 mg/24 hr, 9.5 mg/24 hr
1) Treatment of moderately severe dementia associated with Parkinson’s disease in patients who have behavioural symptoms
2) Treatment of moderately severe dementia associated with Alzheimer’s disease in patients who have behavioural symptoms.
Conditions should be confirmed by a specialist physician (geriatrician, neurologist or psychiatrist) with experience in the treatment of dementia. Treatment should be continued only when it is considered to be having a worthwhile effect on cognitive, global functional or behavioural symptoms